Ergotamine has been used to treat acute attacks of migraine for just on a century, first as an ingredient of an extract of ergot, and more recently as the pure substance. For a drug to have survived so long in clinical practice is testimony to its effectiveness. However there are several problems in using ergotamine that might be illuminated by clinical pharmacokinetic study. Thus the difference between the parenteral dose (0.25-0.50 mg) and the clinically equivalent oral dose (2.0-4.0 mg), and the tendency for oral administration to prove less effective than parenteral therapy, raise the possibility that the drug is incompletely bioavailable when taken by mouth. The ever-present fear of inducing ergotism whenever the drug is prescribed indicates the need to study the relation between plasma concentrations of ergotamine and its biological effects. Such clinical pharmacokinetic investigations require a drug assay of sufficient sensitivity and specificity. Until recently no such assay was available for ergotamine.
The problem with assay sensitivity arises because ergotamine is used therapeutically in so low a dose that measurement of subnanogram quantities is desirable. The techniques which might yield a sufficiently sensitive assay include fluorescence spectrophotometry, gas chromatography with electron-capture detection, high performance liquid chromatography with fluorescence or electrochemical detection, gas (or perhaps the newly developed high performance liquid) chromatography-mass spectrometry, and various types of immune assay (principally radio-immune assay). Ergotamine fluoresces strongly, and some published assays for the drug have depended on fluorescence detection. No adequate gas chromatographic assays appear to have been described, and one's experience with gas chromatography-mass spectrometry of the drug, underivatized or derivatized, is that the molecule undergoes so much thermal decomposition that adequate assay sensitivity cannot be obtained. A radio-immune assay of reasonably adequate sensitivity is now available (1) .
There are two main sources of non-specificity in ergotamine assays. In aqueous solution ergotamine isomerises over some hours to its epimer ergotaminine, which is relatively inactive biologically. At equilibrium, some 60% of the original ergotamine content remains as the biologically active isomer (this also applies to the contents of ergotamine solutions for injection). Unless it could be shown that the isomers had identical pharmacokinetics, a satisfactory assay for the drug should measure only the active isomer ergotamine. The published radio-immune assay for ergotamine is suspect on this ground. However, the two isomers can be separated by high performance liquid chromatography (2, 3) . The second source of assay non-specificity arises because the metabolites of ergotamine are incompletely known (4) and the drug appears to be eliminated mainly by metabolism. In this circumstance an assay involving a highly selective separation process e.g. high performance liquid chromatography, would offer a better chance of measuring the parent substance only than does an assay without a separation step (e.g. radio-immune assay).
Thus, high performance liquid chromatography with fluorescence detection appears to offer the best prospect for an adequate assay of ergotamine at biological concentrations. Edlund (3) has developed such an assay, with a sensitivity adequate for some pharmacokinetic work in man.
The story of attempts to study the pharmacokinetics of ergotamine in man should be interpreted in relation to the sensitivity and specificity of the assays used in the various studies.
A preliminary study of ergotamine kinetics during attacks of migraine was described by Eadie (5) . The assay method (6) used fluorescence spectrometry but proved not sensitive enough to measure the drug for longer than 5-10 min after intravenous injection. No calculation of pharmacokinetic parameters was possible, though there was an impression of a distribution phase half-life of the order of a few minutes. In two subjects, 3-5 min after ergotamine injection, a substance with a different fluorescence emission wave length peak from that of ergotamine began to appear in plasma. It was suggested that this might represent a metabolite of the drug. Later, Sutherland et al. (7) used the same assay to show that it was unlikely that sublingual administration of ergotamine would lead to useful absorption of drug into the circulation.
A series of studies in man with radioactive ergotamine followed. These showed:
(i) apparently increased and faster ergotamine absorption after oral administration when the drug was taken with caffeine than when taken alone (8);
(ii) an invasion half-time of 0.38 h after oral administration, a fast elimination half-time of 6.6 h and a slow (terminal) elimination half-time of 34.3 h, with 3-4% of the dose being excreted unchanged in urine (9); and (iii) elimination half-lives of 2.7 ± 0.9 h (a phase) and 21 ± 4h (ß phase), with a time to achieve peak plasma level (Tmax) of 2.1 ± 0.8 h after oral administration and an oral bioavailability of 62 ± 3% (10).
The validity of many of these findings is uncertain, because metabolites were probably measured with the parent drug, and the metabolites may have been more slowly eliminated than the parent substance.
Several studies of ergotamine pharmacokinetics have employed radio-immune assay of the drug. Schran et al. (1) published a mean plasma level-time curve based on four subjects given a 4 mg oral ergotamine dose, but did not provide calculated pharmacokinetic parameters. Orton (11) described some ergotamine plasma level measurements in healthy volunteers, migraine sufferers during attacks and persons who took ergotamine overdoses. No pharmacokinetic parameters were calculated, but there was some tentative evidence of impaired ergotamine absorption after oral administration during migraine attacks. In a series of publications Ala-Hurula and his co-workers, reported (ii) evidence of the accumulation of ergotamine or an immuno-reactive metabolite as time passed, evidence of poor oral bioavailability in some subjects taking the drug chronically, and in four subjects CSF ergotamine measurements which were probably reasonably similar to simultaneous plasma ergotamine levels (13) .
(iii) some correlation between therapeutic benefit in migraine and plasma ergotamine concentrations (14) .
Hovdal et al. (15) found a mean peak plasma ergotamine concentration of 1.27 ± S.E.M. 0.7 μg/ml 0.5 h after a 0.5 mg intramuscular injection of ergotamine tartrate, a mean plasma level of only 0.44 μg/ml with a broad peak between 0.75 and 2 h after a 4 mg rectal dosage and almost unmeasurable levels after a 2 mg rectal dosage. CSF ergotamine levels were unmeasurable (below 1 ng/ml) when simultaneous plasma ergotamine levels were up to 1.29 ng/ml. No other pharmacokinetic parameters were calculated from the plasma level data, though inspection of the plasma level-time curve published suggests an elim-ination half-life of about 3 h. The findings of these radio-immune assay studies suggest a substantially impaired bioavailability of the drug after oral and rectal administration. The differences in the CSF findings between Ala-Hurala et al. (13) and Hovdal et al. (15) are difficult to explain. The validity of some of the results is uncertain because much of the work was carried out near the limit of sensitivity of an assay which may not have distinguished between ergotamine, its isomer and its metabolites.
Ekbom et al. (16) were the first to use the. inherently more specific and equally sensitive HPLC-fluorescence detection assay to study plasma ergotamine levels (in patients taking 2-4 mg oral ergotamine daily for several days to prevent cluster headache). No measurable drug was found in plasma. The oral bioavailability of the ergotamine must have been less than 1%. Despite this, the ergotamine therapy prevented attacks in some subjects. Tfelt-Hansen et al. (17) used the same assay to show that 2 mg sublingual doses of ergotamine failed to produce detectable plasma concentrations of the drug. Waldenlind et al. (18) found that the half-life of ergotamine was 1.8 h, and that the drug given by oral, inhalational or rectal route, had a bioavailability of less than 2%. It was noticeable, however, that in the first half hour after administration of ergotamine by inhalation the plasma ergotamine levels quoted were distinctly higher than those after administration of the drug by swallowing or rectal insertion. Ibraheem et al. (19) were able to determine formal pharmacokinetic parameters after intravenous administration of 0.5 mg ergotamine, using the HPLC-fluorescence detection assay. The distribution (a-phase) half-life was 0.051 ± S.D. 0.11 h, the terminal (ß-phase) elimination half-life 1.86 ± S.D. 0.34 h, the clearance 0.68 ± S.D. 0.24 L.kg -1 h -1 and the V D (ß) 1.85 ± S.D. 0.77 L.kg -1 . The terminal half-life after intramuscular administration was 2.34 ± S.D. 0.40h, and the bioavailability by this route was 46.6 ± 12.7%.
All the various published fragments of pharmacokinetic data, considered critically and taken in conjunction with the study of Ibraheem et al. (19) suggest that ergotamine is a drug with a relatively rapid elimination, a high clearance (by metabolism), and a very incomplete bioavailability due to presystemic elimination (the 'first-pass' effect) if it is administered by any route which allows it to pass through the liver before it reaches the general circulation. The drug's biological effects appear to last a good deal longer than its short elimination half life would suggest. Thus Tfelt-Hansen et al. (20) found vascular effects of ergotamine persisting 24 h after therapeutic dosage, while clinically the drug given orally three times a day often suffices to prevent attacks of cluster headache. It may therefore be that ergotamine is biologically active at concentrations below those detectable by current ergotamine assays, and has a slower true terminal elimination phase which has not yet been detected. Alternatively, the biological activity that arises from ergotamine may be partly due to one, or more, of its metabolites. This point needs to be settled. Such a metabolite might provide a very much more reliable oral therapy for migraine attacks than oral ergotamine does. In thinking about the treatment of migraine with ergotamine, it may prove more relevant to consider the pharmacokinetics of the postulated metabolite(s) than those of ergotamine.
The information already available about ergotamine pharmacokinetics has several implications for medicine, if it is assumed that unmetabolised ergotamine has a reasonable amount of pharmacological activity in its own right. The low oral and rectal bioavailability of ergotamine would contribute to the inconsistency of therapeutic response to the drug when given by these routes. If the bioavailability is really less than 2%, a difference of bioavailability of only 0.5% could mean a difference of something of the order of 50% in plasma ergotamine levels. More extensive (though cautious) dosage explorations with oral ergotamine than have been customary in clinical practice might benefit a number of patients, though one would have to be extremely wary of increasing dosage if liver disease were present. More attention might be given to ergotamine administration routes which bypass the liver, e.g. intramuscular administration, absorp-tion from the surfaces of the upper alimentary and respiratory tracts, and from the skin. In this connection the pharmaceutical industry might attempt to develop more suitable dosage forms than those which have been available, though the results of Waldenlind et al. (18) with ergotamine sprays (from which the drug probably absorbs largely from the mucosa of the mouth and upper respiratory tract) raise the possibility that this type of preparation, in more suitable dosage, might provide reasonably efficient therapy for migraine attacks.
Gradually, knowledge is becoming available which may change the basis of therapy with a very old drug from clinical empiricism to some degree of scientific rationale.
